Compare AbCellera Biologics Inc (ABCL) vs Las Vegas Sands Corp. (LVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs Las Vegas Sands Corp. — how do they compare? AbCellera Biologics Inc trades at $10.04 (market cap $2.99B), while Las Vegas Sands Corp. trades at $45.72 (market cap $29.44B). The key difference: Las Vegas Sands Corp. is far larger — about 9.8× AbCellera Biologics Inc's market cap, and Las Vegas Sands Corp. pays a 2.64% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | LVS | |
|---|---|---|
Market Cap | $2.99B | $29.44B |
Sector | Health | Consumer Cyclical |
52-Week High | $9.76 | $69.49 |
52-Week Low | $2.78 | $44.78 |
Enterprise Value | $2.58B | $41.33B |
Dividend Yield | — | 2.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABCL's stock rose 7.07% to $10.00, buoyed by positive Phase 2 trial results for its menopause drug ABCL635, which demonstrated an 83% reduction in hot flashes (Business Wire, August 10, 2026). Despite negative profitability margins and cash burn, technical indicators show a bullish trend with strong moving average support. The company maintains a solid balance sheet with $625.61 million in cash and low debt, though revenue declined from $485 million in 2022 to $75 million in 2025.
The outlook hinges on clinical success and monetization of ABCL635, with a consensus price target of $15.50 implying 55% upside. Key risks include prolonged cash burn, drug development setbacks, and competitive pressures. Analyst sentiment is overwhelmingly bullish (91.67% buy ratings), but investors must weigh high valuation multiples against unproven commercial traction.
LVS trades at $45.68, up 0.48% on the day, with a bearish technical signal from moving averages but neutral oscillators. Revenue grew to $13.02B in 2025, with net income of $1.63B and a 12.59% margin. Recent earnings show mixed results, beating in Q4 2025 and Q1 2026 but missing in Q2 2026. The company maintains strong profitability metrics, including a 48.52% gross margin and 134.29% ROE. Positive news includes ESG recognitions and community initiatives, supporting a stable operational outlook.
The stock presents a buy opportunity with a consensus price target of $60.75, implying 33% upside, backed by 59% analyst buy ratings. Risks include high debt levels, with a debt-to-asset ratio of 73.15% in 2025, and sensitivity to macroeconomic factors affecting the gaming and tourism sectors. Institutional sentiment remains positive, but investors should monitor debt management and regional economic conditions for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.
Read more on LVS →
